Multiple Sclerosis (MS): Body Impacts, Treatments, and Living Well
MS is a chronic immune-mediated demyelinating disease of the central nervous system (brain, spinal cord, optic nerves). Onset typically 20–40 years; 3:1 female:male.
Common Symptoms
- Fatigue (80%), weakness, spasticity
- Numbness, paresthesia, Lhermitte's sign
- Vision loss (optic neuritis), diplopia, nystagmus
- Ataxia, gait impairment, tremor
- Bladder/bowel dysfunction, sexual dysfunction
- Cognitive changes (processing speed, memory)
- Depression, anxiety
Disease Courses
- Relapsing-Remitting (RRMS) — 85% at onset
- Secondary Progressive (SPMS)
- Primary Progressive (PPMS) — 15%
Disease-Modifying Therapies (DMTs)
- Injectables: Interferon-β, glatiramer acetate
- Oral: Dimethyl fumarate, fingolimod, siponimod, teriflunomide, cladribine
- Infusion: Natalizumab, ocrelizumab, alemtuzumab, ofatumumab
- Mechanisms: Immune modulation, sequestration, depletion, BBB protection
Symptomatic & Rehabilitative Care
- Dalfampridine (walking), baclofen/tizanidine (spasticity), anticholinergics (bladder)
- PT/OT, cognitive rehab, psychological support
Resources
- National MS Society (NMSS)
- MS International Federation
- Specialized MS centers (multidisciplinary)
Early DMT initiation improves long-term outcomes. Treat to target: no evidence of disease activity (NEDA).
Multiple Sclerosis - Related Articles
- Understanding the Main Types of Multiple Sclerosis
- Multiple Sclerosis in Children: Symptoms, Diagnosis & Understanding
- Understanding MS Exacerbations: Causes and Management
- Multiple Sclerosis (MS) Symptoms: Understanding the Signs
- Primary Progressive MS: Symptoms, Causes & What to Expect
- Understanding the Psychological Impact of Multiple Sclerosis
- Multiple Sclerosis & Diet: The Benefits of a Low-Sugar Approach
